All News

lung%2Cbright.jpg

MMWR: Idiopathic Pulmonary Fibrosis Mortality in the United States

d MMWR

Idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and worsening lung function, has a poor prognosis. An estimated 21% of IPF deaths might be attributable to occupational exposures.

Read Article
hospital.ER_.jpg (keep)

ED Utilization by Psoriatic and Spondyloarthritis Patients

d Jack Cush, MD

A cohort analysis of ambulatory emergency department (ED) utilization by patients with psoriatic arthritis (PsA) and radiographic axial spondyloarthritis (r-axSpA) demonstrated significant use for less urgent and nonurgent health issues, particularly in rural settings.

Read Article
397_relapsing_polychondritis_slide_4_springer_high.jpg

A Review of Relapsing Polychondritis

d Jack Cush, MD

A current review in the Journal of Thoracic Disease on relapsing polychondritis (RP), suggests that while this rare disorder may have an uncertain pathogenesis, its diagnosis and therapeutical management has improved.

Read Article
microbiome,blue

Crohn’s Microbiome may Predispose to Axial Spondyloarthritis

d EurekAlert!

People with Crohn’s disease and related joint inflammation linked to immune system dysfunction have distinct gut bacteria or microbiota, with the bacterium Mediterraneibacter gnavus being a potential biomarker, according to new study by Weill Cornell Medicine researchers.

Read Article
Blood labs

Normalizing Serologies Enhances Remission in SLE

d Jack Cush, MD

Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.

Read Article
Knee,injection

Intraarticular Steroids in OA Lowers Need for Pain Meds

d MedPage Today

Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids?

Read Article
Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb; Gazyva) for the Treatment of Lupus Nephritis based on positive results from Phase III REGENCY study. FDA decision by October 2025 https://t.co/Mx3YDUfkMg https://t.co/MTBZo1TCrK

Links:

Dr. John Cush RheumNow ( View Tweet)
Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392 having MS, 7,302 DM, & 25K OA. Having Sleep apnea or disturbances signif incr disability in OA & DM (OR~1.4) as was excessive daytime sleepiness… https://t.co/5PP18gqDqi https://t.co/u1HFOstv8W
Dr. John Cush RheumNow ( View Tweet)
FDA grants priority reviews to: - Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis. - Upadacitinib (AbbVie; JAK inhib) for use in GCA - Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis - Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz -… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8
Dr. John Cush RheumNow ( View Tweet)
SOCS1 Insufficiency - a Rare Inborn Error of Immunity Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor… https://t.co/I0muoIk5GL https://t.co/jbcuAZivci
Dr. John Cush RheumNow ( View Tweet)
Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/cxz4DJ6AUs https://t.co/FlgwykFnfl
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies https://t.co/RZSwrj8as8

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Live 2025 is now available On Demand For the first time, https://t.co/4UQlqwujiR is offering exclusive access to: ✅ 7 STEP Talks from top rheumatology experts ✅ 21 Powerful lectures and Q & A Panels answering real-world questions ✅ All speaker slides and handouts… https://t.co/HokIfxbgTd https://t.co/ztVymFLuRT

Links:

Dr. John Cush RheumNow ( View Tweet)
From Bellyache to Bloodstorm - a Mesenteric Sclerosis case with Macrophage Activation Syndrome Presentation by Dr. Anjali Nidhaan at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/pXwav5f2BI https://t.co/0Faao7zhbV

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/WVErW1RrCj https://t.co/eQVFIZNSRx

Links:

Dr. John Cush RheumNow ( View Tweet)
Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/LRsT1TLEm4 https://t.co/bSi50pDn2O

Links:

Dr. John Cush RheumNow ( View Tweet)
Opioid Deaths are Down (2.28.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week! https://t.co/Lb6F64AlNJ https://t.co/7AjSXOn142

Links:

Dr. John Cush RheumNow ( View Tweet)
Loss of Good Sleep Linked to All-Cause Mortality A US study shows that nearly two-thirds of the population had suboptimal 5-year sleep duration trajectories with a resultant 29% increase in risk of all-cause mortality. https://t.co/GXkIDC2uSQ https://t.co/wYzpnK9BMQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Recurrent Pericarditis in Lupus A study from the Lupus Hopkins Cohort shows that systemic lupus erythematosus (SLE) patients with pericarditis are at risk for recurrence, and likely to be younger patients, with uncontrolled disease, and linkage to higher doses of oral… https://t.co/hML8NfhBy3 https://t.co/cKX5KaSg3a
Dr. John Cush RheumNow ( View Tweet)
Risk of Cancer on JAKi in RA (12 463 vs 38 345 controls). No incr risk of CA w/ exposure to JAKi (adj OR 1.04), TNFi (0.98), other bDMARDs (0.98). But JAKi was assoc w/ signif more lung CA (1.40; esp in males 2.12) & less breast CA (0.62) in women https://t.co/fr3VjPhJve https://t.co/zNehdWBbeI

Links:

Dr. John Cush RheumNow ( View Tweet)
×